California Public Employees Retirement System Purchases 6,563 Shares of IQVIA Holdings Inc. $IQV

Key Points

• CalPERS increased its IQVIA stake by 2.0% in the first quarter, buying 6,563 additional shares and bringing its total to 337,191 shares valued at about $57.5 million.
• IQVIA reported stronger-than-expected quarterly results, posting $2.90 EPS on $4.15 billion in revenue, both above Wall Street estimates, while revenue rose 8.4% year over year.
• The company approved a $2 billion stock buyback and analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $225.71.

California Public Employees Retirement System increased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 337,191 shares of the medical research company's stock after buying an additional 6,563 shares during the period. California Public Employees Retirement System owned 0.20% of IQVIA worth $57,505,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. J. Safra Sarasin Holding AG increased its holdings in shares of IQVIA by 174.3% in the 4th quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company's stock worth $2,891,000 after buying an additional 8,151 shares during the last quarter. CWM LLC lifted its holdings in shares of IQVIA by 23.9% during the 4th quarter. CWM LLC now owns 55,830 shares of the medical research company's stock worth $12,585,000 after acquiring an additional 10,762 shares during the last quarter. Calamos Advisors LLC grew its position in IQVIA by 268.1% in the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company's stock worth $42,536,000 after acquiring an additional 137,441 shares in the last quarter. Franklin Street Advisors Inc. NC purchased a new position in IQVIA in the fourth quarter worth $15,724,000. Finally, HF Advisory Group LLC increased its stake in IQVIA by 1,791.6% in the fourth quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company's stock valued at $34,852,000 after acquiring an additional 146,444 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

IQVIA stock opened at $206.26 on Monday. The firm has a fifty day simple moving average of $185.04 and a two-hundred day simple moving average of $187.88. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $247.04. The company has a market capitalization of $34.42 billion, a PE ratio of 25.56, a P/E/G ratio of 1.85 and a beta of 1.20.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the previous year, the business earned $2.70 earnings per share. The company's quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

IQV has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th. Weiss Ratings upgraded IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday. Morgan Stanley restated an "equal weight" rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Wall Street Zen lowered IQVIA from a "buy" rating to a "hold" rating in a research note on Saturday, June 27th. Finally, Robert W. Baird increased their price target on shares of IQVIA from $230.00 to $249.00 and gave the company an "outperform" rating in a research report on Wednesday, July 1st. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $225.71.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.